Aisha A Alsfouk
Overview
Explore the profile of Aisha A Alsfouk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
312
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Al Kamaly O, Younes A, Ibrahim M, Harras M, Alsfouk A, Sabour R
ACS Omega
. 2025 Feb;
10(4):4044-4056.
PMID: 39926530
MurA is a pivotal target in antimicrobial therapy owing to its fundamental function in bacterial cell wall production; inhibiting this enzyme not only disrupts cell integrity, leading to bacterial lysis,...
2.
Alsfouk A, Othman I, Anwar M, Saleh A, Nossier E
RSC Adv
. 2025 Jan;
15(4):2758.
PMID: 39871970
[This corrects the article DOI: 10.1039/D4RA06744D.].
3.
Alsfouk A, Othman I, Anwar M, Saleh A, Nossier E
RSC Adv
. 2025 Jan;
15(2):1407-1424.
PMID: 39822569
The current work focuses on the creation of novel derivatives of the quinazolinone ring system, with various substituted thiophene, thienopyrimidine, and thienopyridine scaffolds 3a,b-11. Employing the standard MTT assay, every...
4.
Metwaly A, El-Fakharany E, Alsfouk A, Ibrahim I, Elkaeed E, Eissa I
Curr Med Chem
. 2025 Jan;
PMID: 39757685
Introduction: In our quest to identify potent inhibitors against SARS-CoV-2, an extensive investigation was conducted for the binding and inhibitory efficacy of Rutin against nine SARS-CoV-2 proteins. Method: The first...
5.
Metwaly A, Elkaeed E, Alsfouk A, Ibrahim I, Elkady H, Eissa I
Antivir Ther
. 2024 Dec;
29(6):13596535241305536.
PMID: 39639531
Background: The COVID-19 pandemic has created an urgent need for effective therapeutic agents. The SARS-CoV-2 Main Protease (M) plays a crucial role in viral replication and immune evasion, making it...
6.
Metwaly A, El-Fakharany E, Alsfouk A, Ibrahim I, Elkaeed E, Eissa I
PLoS One
. 2024 Dec;
19(12):e0312866.
PMID: 39625895
To find an effective inhibitor for SARS-CoV-2, Quercetin's chemical structure was compared to nine ligands associated with nine key SARS-CoV-2 proteins. It was found that Quercetin closely resembles Remdesivir, the...
7.
Al Kamaly O, Younes A, Harras M, Sabour R, Alsfouk A, Ibrahim M
BMC Chem
. 2024 Nov;
18(1):226.
PMID: 39538322
A set of innovative N-amino-5-cyano-6-pyridones derivatives was developed and produced using one-pot three-component procedures. The evaluated molecules were examined for their antimicrobial efficacy. Based on the acquired findings, most of...
8.
Alsfouk A, Faris A, Cacciatore I, Alnajjar R
Front Chem
. 2024 Nov;
12:1473398.
PMID: 39498375
Cyclin-dependent kinase 9 (CDK9) and cytochrome P450 3A4 (CYP3A4) have emerged as promising targets in the development of anticancer drugs, presenting a consistent challenge in the quest for potent inhibitors....
9.
Elkady H, Elgammal W, Mahdy H, Zara S, Carradori S, Husein D, et al.
Comput Biol Chem
. 2024 Sep;
113:108221.
PMID: 39332241
In this study, we present the design, synthesis, and evaluation of six new thiadiazole derivatives designed as VEGFR-2 inhibitors. The most promising compound, 18b, demonstrated promising inhibitory activity against VEGFR-2,...
10.
Fawzy M, Ibrahim K, Aly A, Mohamed A, Abdel Hafez S, Abdelzaher W, et al.
Future Med Chem
. 2024 Sep;
16(21):2211-2230.
PMID: 39291539
Pulmonary fibrosis is a life threating disease which requires an immediate treatment and due to the limited medications, this study focused on synthesizing a series of quinoline-based pyrimidodiazepines as a...